Phase II trial with melphalan for percutaneous chemosaturation (CS-PHP-Mephalan) in treating unresectable liver metastases of uveal melanoma

Trial Profile

Phase II trial with melphalan for percutaneous chemosaturation (CS-PHP-Mephalan) in treating unresectable liver metastases of uveal melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2015

At a glance

  • Drugs Melphalan (Primary)
  • Indications Liver metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2015 Results published in Delcath Systems media release.
    • 02 Nov 2015 Results published at the European Association of Dermato Oncology (EADO) annual congress, as per Delcath media release.
    • 02 Nov 2015 Results published in Delcath Systems media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top